cross-strain mRNA vaccine (eTheRNA/EpiVax/ReproCELL)

N/A

Report date: 2026/01/26 17:59:14

Base Information

Drug Namecross-strain mRNA vaccine (eTheRNA/EpiVax/ReproCELL)
Drug Alias NameSARS-CoV-2 RNA vaccine (eTheRNA/EpiVax/ReproCELL)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionCD70 antigen modulatorsToll like receptor 4 agonistsImmunostimulants +[5] 
TargetsToll like receptor 4Tumor necrosis factor receptor superfamily member 5CD70 antigen
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesJapan
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompanieseTheRNA Immunotherapies NV
China Registration ClassN/A

Develop Information

Active CompanieseTheRNA Immunotherapies NVReprocell IncEpiVax Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A